Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

AI-powered analytics and experimental validation: Transforming target identification in drug discovery

Discover how AI-powered analytics and experimental validation combine to improve target identification and accelerate drug discovery success.

From Axxam S.p.A 23 Jul 2026

AI platform uncovers promising target for chronic pain treatmen

Despite the widespread availability of analgesics, pain management remains one of the most significant and pervasive challenges in modern medicine, with more than 20% of the global population suffering from chronic pain, especially chronic neuropathic pain characterized by central sensitization.

22 Jul 2026

AI-powered PeptiVerse could accelerate peptide drug discovery

Penn Engineers have developed PeptiVerse, an AI-powered platform that predicts key chemical and biological properties of peptides, the strings of amino acids whose medical potential has been demonstrated by the success of GLP-1 drugs, the widely used weight-loss treatments.

21 Jul 2026

UC San Diego and IGI join hands to develop advanced genome-editing tools and applications

The University of California San Diego and the Innovative Genomics Institute (IGI), founded by Nobel laureate and CRISPR gene editing co-discoverer Jennifer Doudna, announced a new partnership today to jointly develop cutting-edge genomic tools for addressing large-scale challenges in health and the environment.

21 Jul 2026

Unlocking the untapped 90%: Membrane protein purification as a three hours routine workflow

Automated, detergent-free purification preserves native membrane protein structure while supporting more reliable target validation workflows.

From Analytik Jena 21 Jul 2026

ECT-like brain stimulation triggers unexpected nuclear reprogramming in mature neurons

Nearly 90 years after Ugo Cerletti and Lucio Bini introduced electroconvulsive therapy (ECT), brain stimulation therapies such as ECT and Repetitive Transcranial Magnetic Stimulation (rTMS) are common in psychiatry because they are highly effective for treating depression and schizophrenia, yet their cellular mechanisms remain poorly understood

17 Jul 2026

Computational framework identifies synergistic compound pairs in herbal medicines

Herbal medicines have long been used in disease treatment, often through formulas that combine multiple herbs to enhance therapeutic effects and reduce side effects.

16 Jul 2026

Designing the AI-Enabled Life Sciences Workforce Summit Europe

AI's impact on drug discovery and manufacturing raises critical workforce questions, driving life sciences organizations to rethink skills and leadership.

From Designing the AI-Enabled Life Sciences Workforce Summit Europe 15 Jul 2026

How to connect make and test for faster drug discovery

Discover how connecting make and test workflows can accelerate drug discovery by improving decision-making across the DMTA cycle.

From TTP plc 15 Jul 2026

Building the next generation of DMTA for future-ready drug discovery

Discover how the next generation of DMTA is creating a future-ready drug discovery engine through AI and automation.

From TTP plc 15 Jul 2026

How to overcome purification bottlenecks in modern drug discovery

Learn how to overcome purification bottlenecks in modern drug discovery with advanced purification strategies, streamlined workflows, and automation.

From TTP plc 15 Jul 2026

Unlocking the potential of organoids in modern drug discovery

Explore how organoids are unlocking new possibilities in modern drug discovery by improving disease modelling within DMTA-driven research workflows.

From TTP plc 15 Jul 2026

Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing.

14 Jul 2026

Global consortium releases AI toolbox to unlock new Alzheimer's treatments

The Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-BRAIN), a global collaboration of academic researchers, pharmaceutical companies, and philanthropic organizations of which Washington University School of Medicine in St. Louis is a founding member, today launched three open-source AI tools to accelerate research aimed at developing new treatments for Alzheimer's disease and other neurodegenerative diseases.

13 Jul 2026